Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1503918 | 0.85 | — | — | |
| SCHEMBL16508916 | 0.84 | CYP3A4 (0.40) | CYP4F2CYP4A11CYP3A4CYP2C9PKM | |
| SCHEMBL6731550 | 0.82 | CYP3A4 (0.39) | CYP4F2CYP4A11CYP3A4CYP2C9PKM | |
| SCHEMBL3881240 | 0.82 | CYP3A4 (0.39) | CYP4F2CYP4A11CYP3A4CYP2C9PKM | |
| SCHEMBL15268888 | 0.82 | CYP2C19 (0.39) | CYP4F2CYP4A11CYP3A4CYP2C9PKM | |
| SCHEMBL761603 | 0.81 | CYP4F2 (0.61) | CYP4F2CYP4A11CYP3A4CYP2C19NPSR1 | |
| SCHEMBL3952155 | 0.81 | CYP4F2 (0.56) | CYP4F2CYP4A11CYP3A4CYP2C19NPSR1 | |
| SCHEMBL1747956 | 0.81 | CYP2C19 (0.41) | CYP4F2CYP4A11CYP3A4CYP2C9PKM | |
| Hydrochloric Acid SCHEMBL29624769 | 0.81 | CYP2C19 (0.38) | CYP4F2CYP4A11CYP3A4CYP2C9PKM | |
| SCHEMBL6782433 | 0.81 | TSHR (0.42) | CYP3A4CYP2C19NPSR1ALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3389380-B1 | SPIROCYCLIC QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-07-21 | — | — | EP | disclosed |
| US-10544155-B2 | Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10544155-B2 | Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190040076-A1 | Spirocyclic Quinolizine Derivatives Useful as HIV Integrase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-02-07 | — | — | US | disclosed |
| US-20190040076-A1 | Spirocyclic Quinolizine Derivatives Useful as HIV Integrase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-02-07 | — | — | US | disclosed |
| EP-3389380-A1 | SPIROCYCLIC QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-3092229-B1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-3092229-B1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-28 | — | — | EP | disclosed |
| WO-2017106071-A1 | SPIROCYCLIC QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017106071-A1 | SPIROCYCLIC QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2015103509-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015103509-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-09 | — | — | WO | disclosed |
| US-20140088124-A1 | IMIDAZOLE DERIVATIVES | INTERVET INC. | 2014-03-27 | — | — | US | disclosed |
| US-20140088124-A1 | IMIDAZOLE DERIVATIVES | INTERVET INC. | 2014-03-27 | — | — | US | disclosed |
| US-20140088124-A1 | IMIDAZOLE DERIVATIVES | INTERVET INC. | 2014-03-27 | — | — | US | disclosed |
| WO-2012164071-A1 | IMIDAZOLE DERIVATIVES | INTERVET INTERNATIONAL B.V. (NL) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012164071-A1 | IMIDAZOLE DERIVATIVES | INTERVET INTERNATIONAL B.V. (NL) | 2012-12-06 | — | — | WO | disclosed |
| US-7968572-B2 | Nitrogen-containing heterocyclic compound and pharmaceutical application thereof | ONO PHARMACEUTICALS CO., LTD. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20100063104-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | ONO PHARMACEUTICAL CO., LTD., (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-1932840-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544155-B2 | Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors | NQO2, SIRT5, CCR5 | CYP4F2 628/4885CYP4A11 215/4885CYP3A4 95/4885 |
| US-20190040076-A1 | Spirocyclic Quinolizine Derivatives Useful as HIV Integrase Inhibitors | NQO2, SIRT5, CCR5 | CYP4F2 628/4885CYP4A11 215/4885CYP3A4 95/4885 |
| US-20140088124-A1 | IMIDAZOLE DERIVATIVES | DGAT1, DGAT2, SOAT1 | CYP4F2 465/4885CYP4A11 980/4885CYP3A4 2220/4885 |
| US-20100063104-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | NOS2, NOS1, MAPK1 | CYP4F2 1127/4885CYP4A11 164/4885CYP3A4 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.